Details

Autor(en) / Beteiligte

• van der Lelie, Daniel
• Oka, Akihiko
• Taghavi, Safiyh
• Umeno, Junji
• Fan, Ting-Jia
• Merrell, Katherine E.
• Watson, Sarah D.
• Ouellette, Lisa
• Liu, Bo
• Awoniyi, Muyiwa
• Lai, Yunjia
• Chi, Liang
• Lu, Kun
• Henry, Christopher S.
• Sartor, R. Balfour

Titel

Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis

Ist Teil von

• Nature communications, 2021-05, Vol.12 (1), p.1-17, Article 3105

Ort / Verlag

London: Nature Publishing Group

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Abstract Environmental factors, mucosal permeability and defective immunoregulation drive overactive immunity to a subset of resident intestinal bacteria that mediate multiple inflammatory conditions. GUT-103 and GUT-108, live biotherapeutic products rationally designed to complement missing or underrepresented functions in the dysbiotic microbiome of IBD patients, address upstream targets, rather than targeting a single cytokine to block downstream inflammation responses. GUT-103, composed of 17 strains that synergistically provide protective and sustained engraftment in the IBD inflammatory environment, prevented and treated chronic immune-mediated colitis. Therapeutic application of GUT-108 reversed established colitis in a humanized chronic T cell-mediated mouse model. It decreased pathobionts while expanding resident protective bacteria; produced metabolites promoting mucosal healing and immunoregulatory responses; decreased inflammatory cytokines and Th-1 and Th-17 cells; and induced interleukin-10-producing colonic regulatory cells, and IL-10-independent homeostatic pathways. We propose GUT-108 for treating and preventing relapse for IBD and other inflammatory conditions characterized by unbalanced microbiota and mucosal permeability.